Features of patients with uveitis associated with juvenile idiopathic arthritis required eye surgery

Table 1 Descriptive statistic characteristics of the studied population

Parameter	Result
Sex, females	44 (64.7)
HLA-B27-positivity	7 (22.6)
ANA positivity	41 (61.2)
Type of arthritis
Oligoarthritis	43 (63.2)
ERA	11 (16.2)
Psoriatic arthritis	2 (2.9)
Undifferentiated arthritis	12 (17.7)
Age at onset of uveitis, years	7.0 (4.4-9.6)
Patients who underwent eye surgery	17 (25.0)
Time to eye surgery, years	2.5 (1.1-6.6)
MTX therapy	55.0 (80.9)
Time to MTX initiation, years	0.33 (0.08-1.48)
Remission achieved on MTX	39 (70.9)
Time to remission on MTX, years	0.33 (0.25-0.58)
Patients who flared on MTX	25 (46.3)
Time to first flare on MTX, years	0.6 (0.3-1.1)
bDMARDs received	44 (64.7)
Time to initiation of bDMARD therapy, years	1.62 (0.65-3.67)
Remission achieved on bDMARD therapy	35 (77.8)
Time to remission, years	0.2 (0.1-0.4)
Flare on bDMARD therapy	18 (52.9)
Time to first flare on bDMARD therapy, years	1.6 (0.8-2.5)
Received intraocular corticosteroids	32 (47.1)
Time to intraocular corticosteroid injection, years	0.08 (0.00-1.80)
Time between MTX and bDMARD therapy, years	1.0 (0.4-1.5)

Data are presented as n (%). HLA-B27: Human leukocyte antigen-B27; ANA: Antinuclear antibody; ERA: Enthesitis-related arthritis; MTX: Methotrexate; bDMARDs: Biological disease-modifying antirheumatic drugs.

Table 2 Comparative analysis of uveitis associated with juvenile idiopathic arthritis patients for surgical vs non-surgical management

Parameter	Eye surgery, n = 17	No eye surgery, n = 51	P value
Sex, female	11 (64.7)	33 (64.7)	1.000
Age at arthritis onset, years	3.1 (2.2-5.9)	6.5 (3.0-10.7)	0.056
Age at uveitis onset, years	4.9 (3.7-8.2)	7.8 (4.7-10.8)	0.017
Anatomical type of uveitis
Posterior	1 (5.9)	3 (5.9)	0.553
Panuveitis	5 (29.4)	8 (15.7)
Pars planitis	0 (0.0)	2 (3.9)
Anterior	11 (64.7)	38 (74.5)
Acute manifested uveitis	6 (35.3)	21 (41.2)	0.779
Unilateral uveitis	6 (35.3)	23 (45.1)	0.577
Complications at first examination	7 (41.2)	14 (27.5)	0.366
ESR at onset, mm/hour	24.0 (19.5-41.5)	18.5 (8.3-34.3)	0.551
CRP at onset, mg/L	18.0 (9.5-75.5)	2.1 (1.0-14.7)	0.358
Active joints	1.0 (1.0-1.5)	2.0 (1.0-2.0)	0.109
Age at uveitis onset under 7 years	12 (70.6)	22 (43.1)	0.091
ANA-positive	9 (56.3)	32 (62.7)	0.770
HLA-B27-positive	2 (25.0)	5 (21.7)	1.000
Time to MTX initiation, years	0.75 (0.30-1.70)	0.25 (0.10-0.70)	0.057
Time to remission on MTX, years	0.58 (0.40-1.10)	0.28 (0.20-0.40)	0.036
Time to first flare, years	0.59 (0.50-1.10)	0.53 (0.30-1.00)	0.679
Remission on MTX	6 (42.9)	33 (80.5)	0.015
Loss of disease control	5 (38.5)	20 (48.8)	0.545
Intraocular corticosteroid injections	9 (52.9)	24 (47.1)	0.782
bDMARD therapy	15 (88.2)	29 (56.9)	0.021
Time to bDMARD initiation, years	2.3 (1.1-5.3)	1.3 (0.5-3.5)	0.065
Remission on bDMARDs	11 (73.3)	24 (80.0)	0.710
Time to remission on bDMARDs, years	0.17 (0.08-0.30)	0.20 (0.08-0.40)	0.810
Flare on bDMARDs	8 (66.7)	10 (45.5)	0.297
Time to first flare on bDMARDs, years	1.0 (0.3-2.0)	1.9 (1.4-3.0)	0.323

Data are presented as n (%). ESR: Erythrocytes sedimentation rate; CRP: C-reactive protein; ANA: Antinuclear antibody; HLA-B27: Human leukocyte antigen-B27; MTX: Methotrexate; bDMARDs: Biological disease-modifying antirheumatic drugs.